The significant outperformance of Viking Therapeutics in the market, with an annualized return of 47.44% over the past 5 years, indicates strong company performance and investor confidence. This historical performance, coupled with a current market capitalization of $8.31 billion, suggests a positive outlook for VKTX in the short term, assuming no negative market or company-specific events occur.